

RETATRUTIDE 60mg is available as an individual research compound. Researchers can review its product record and supporting documentation, including a linked original laboratory report. This product is supplied for laboratory research purposes only and is not for human or animal consumption.
Every Evora batch is third-party tested before release. See the certificate of analysis on our COAs page.
Loading reviews…
Choose the right injection area
Use the abdomen or the upper legs. Divide the area you choose into four sections and move to a new section each week, so the same spot is not used again too soon.
- Abdomen or upper legs
- Switch injection sites weekly
- At least one finger width from the last injection
- At least 5 cm away from the navel
General guidance only. Always follow the instructions supplied with your product.
UK delivery is a flat £10.00 with tracking (international £35.00). Orders placed before 2pm Monday to Friday are dispatched the same day.
International shipping is available to selected countries. See our shipping policy for details.
RETATRUTIDE 60mg: product information
Retatrutide 60mg is supplied as a lyophilised research peptide. Retatrutide, also known by its research code LY3437943, is an investigational peptide that acts on three receptors: GIP, GLP-1 and glucagon, which is why it is often called a triple agonist. It is being studied in Phase 3 clinical trials (the TRIUMPH programme) and is not a licensed medicine in the UK.
Frequently asked questions
What is retatrutide?
Which retatrutide strengths are available?
Retatrutide vs tirzepatide?
Is there a certificate of analysis?
How should it be stored?
How much is delivery?
Related products: RETATRUTIDE 20mg · RETATRUTIDE 40mg · RETAKLIK 2.0 (RETATRUTIDE + CAGRILINTIDE) 30+5mg · KLIKJARO (TIRZEPATIDE) 40mg · Lab reports (COAs)


